Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
ACS Medicinal Chemistry Letters
|
June 16, 2022
Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists
Nicholas R Wurtz, James A Johnson, Andrew Viet, et al.
Journal of Medicinal Chemistry
|
July 26, 2016
Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex
Xiaojun Zhang, Peter W Glunz, James A Johnson, et al.
ACS Medicinal Chemistry Letters
|
January 8, 2019
Potent Triazolopyridine Myeloperoxidase Inhibitors
Nicholas R Wurtz, Andrew Viet, Scott A Shaw, et al.
Journal of Medicinal Chemistry
|
May 15, 2020
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure
Yoshikazu Asahina, Nicholas R Wurtz, Kazuto Arakawa, et al.
ACS Pharmacology & Translational Science
|
October 21, 2022
Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial Infarction
John Lupisella, Stéphane St-Onge, Marilyn Carrier, et al.
EMBO Molecular Medicine
|
April 3, 2025
Formyl-peptide receptor type 2 activation mitigates heart and lung damage in inflammatory arthritis
Andreas Margraf, Jianmin Chen, Marilena Christoforou, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors
Xiaojun Zhang, Wen Jiang, Swanee Jacutin-Porte, et al.
ACS Medicinal Chemistry Letters
|
September 18, 2024
Discovery and Optimization of Aryl Piperidinone Ureas as Selective Formyl Peptide Receptor 2 Agonists
Nicholas R Wurtz, Pravin S Shirude, Daniel L Cheney, et al.
Medchemcomm
|
August 16, 2018
Triazolopyrimidines identified as reversible myeloperoxidase inhibitors
Franck Duclos, Lynn M Abell, David G Harden, et al.
JACC. Basic to Translational Science
|
January 8, 2020
Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment
Ricardo A García, Bruce R Ito, John A Lupisella, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
ACS Medicinal Chemistry Letters
|
June 16, 2022
Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists
Nicholas R Wurtz, James A Johnson, Andrew Viet, et al.
Journal of Medicinal Chemistry
|
July 26, 2016
Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex
Xiaojun Zhang, Peter W Glunz, James A Johnson, et al.
ACS Medicinal Chemistry Letters
|
January 8, 2019
Potent Triazolopyridine Myeloperoxidase Inhibitors
Nicholas R Wurtz, Andrew Viet, Scott A Shaw, et al.
Journal of Medicinal Chemistry
|
May 15, 2020
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure
Yoshikazu Asahina, Nicholas R Wurtz, Kazuto Arakawa, et al.
ACS Pharmacology & Translational Science
|
October 21, 2022
Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial Infarction
John Lupisella, Stéphane St-Onge, Marilyn Carrier, et al.
EMBO Molecular Medicine
|
April 3, 2025
Formyl-peptide receptor type 2 activation mitigates heart and lung damage in inflammatory arthritis
Andreas Margraf, Jianmin Chen, Marilena Christoforou, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors
Xiaojun Zhang, Wen Jiang, Swanee Jacutin-Porte, et al.
ACS Medicinal Chemistry Letters
|
September 18, 2024
Discovery and Optimization of Aryl Piperidinone Ureas as Selective Formyl Peptide Receptor 2 Agonists
Nicholas R Wurtz, Pravin S Shirude, Daniel L Cheney, et al.
Medchemcomm
|
August 16, 2018
Triazolopyrimidines identified as reversible myeloperoxidase inhibitors
Franck Duclos, Lynn M Abell, David G Harden, et al.
JACC. Basic to Translational Science
|
January 8, 2020
Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment
Ricardo A García, Bruce R Ito, John A Lupisella, et al.
Page
of 3